Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
ALD403 (Eptinezumab)
BIOLOGICAL
2 trials
Sponsors
Alder Biopharmaceuticals, Inc.
Conditions
Migraine Disorder
Migraine Disorders
Phase 3
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
Completed
NCT02974153
Alder Biopharmaceuticals, Inc.
Migraine Disorders
Start: 2016-11-30
End: 2018-04-30
Updated: 2020-06-09
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
Completed
NCT02985398
Alder Biopharmaceuticals, Inc.
Migraine Disorder
Start: 2016-12-31
End: 2019-03-31
Updated: 2020-04-21
Related Papers
Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.
2026-04-17
Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures.
2024-12-12
2 citations
Prevalence of Migraine in Saudi Arabia and the Proposed Introduction of Eptinezumab: A Pooled and Meta-Analysis from Clinical Rrials.
2024-04-30
Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine.
2023-06-28
P.015 Preventive treatment with eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2023-06-01
Lack of “wearing off” effect with eptinezumab in the preventive treatment of migraine (P13-12.009)
Neurology
2023-04-25
Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2 (S47.006)
Neurology
2023-04-25
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
BMC Neurology
2022-10-25
5 citations
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
The Journal of Headache and Pain
2022-09-06
6 citations
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
BMC Neurology
2022-07-08
15 citations
P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2022-06-01
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
2022-04-18
6 citations
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
Cephalalgia
2022-03-25
17 citations
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
Cephalalgia
2022-03-18
22 citations
Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
The Journal of Headache and Pain
2022-02-21
11 citations
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
The Journal of Headache and Pain
2022-02-07
7 citations
Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
Clinical Therapeutics
2022-02-05
17 citations
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
2021-11-25
9 citations
P.034 Eptinezumab Demonstrated Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2021-11-01
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
Headache The Journal of Head and Face Pain
2021-09-22
42 citations
7 more papers not shown